The panel of experts at the ISP felt strongly that localization of pheochromocytoma or paraganglioma should only be initiated if the clinical evidence for the presence of tumor is reasonably ...

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

A pheochromocytoma tumor ... went through with treatment for the tumor in October and suffered a setback post-surgery, but earlier today, she provided an uplifting update on her X account.

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA ...

Measurement of both metanephrine and normetanephrine, therefore, had a sensitivity of 100% in identifying pheochromocytoma. Overall, 17 patients were assessed before and after surgery ...

The patient underwent surgery, which confirmed a malignant neck paraganglioma with metastasis to a cervical lymph node. He had no family history of carotid body tumors or pheochromocytoma.

Bilateral optic disc swelling is an important clinical sign that can reflect a variety of inflammatory, infectious, toxic, metabolic, genetic, or vascular conditions, such as hypertension. [1] It ...

Monitor HR during therapy. Bronchospastic disease. Pheochromocytoma. Surgery. Diabetes. May mask signs and increase risk for hypoglycemia. Hyperthyroidism. Avoid abrupt cessation. Hepatic impairment.